spec sheet10 rows
1cP-LSD (1-cyclopropanoyl-LSD) is a widely distributed lysergamide bearing a cyclopropylcarbonyl group on the indole nitrogen of LSD. Incubation with human serum generates LSD, indicating that it acts as a prodrug in vivo, and it induces the LSD-like head-twitch response in mice with a median effective dose comparable to 1P-LSD; the liberated LSD produces the classic serotonergic psychedelic experience through 5-HT2A receptor agonism. Because of its close correspondence to LSD, it has become one of the most popular legal-grey lysergamides and has even been the subject of exploratory low-dose veterinary studies examining anxiety and welfare in dogs. Analytical, metabolic, and in silico toxicological investigations have characterized its detection, stability, and predicted hazard profile.
- Very LSD-like experience
- Long duration
- Reliable visual and cognitive character
- Cyclopropanoyl LSD prodrug, LSD-equivalent effects
- Anxiety in the wrong setting
- Vasoconstriction
- Insomnia after use
Mechanism
The active molecule acts chiefly as a partial at the receptor, the main driver of the psychedelic state, with further activity at 5-HT2C, , and receptors. The 1-cyclopropanoyl group is thought to be cleaved after dosing to release LSD, so 1cP-LSD behaves like a delivery form of LSD. Users generally report it as roughly as potent as LSD, consistent with efficient conversion.
receptor fingerprint
receptorpartial agonist (via LSD)
5-HT2C receptoragonist
receptoragonist
Safetyrisks and cautions, not medical advice
It is one of the more popular LSD prodrugs and is generally reported as close to LSD in strength, but it remains a research chemical without formal safety data. Avoid with a personal or family history of psychosis or bipolar disorder, and never combine lysergamides with MAOIs or strongly serotonergic drugs (serotonin toxicity), or with lithium or tramadol (seizure reports). Not medical advice.
Subjective profileweighing the evidence above
Functionally a way of taking LSD with an extra step, so the risk profile is LSD's own plus the uncertainty of unregulated material and no formal safety data. Not casual territory, and off the table entirely with a psychosis or bipolar history, or with lithium, tramadol or anything serotonergic on board.
Resources
This entry is here for reference.
Research
- 2017first citedCrystal Structure of an LSD-Bound Human Serotonin Receptor.
- 2020most active year3 papers
- 2026most recentThe toxicity of psychedelic LSD derivatives: 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD), 1…
- 1.The toxicity of psychedelic LSD derivatives: 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD), 1-butyryl-LSD (1B-LSD), 1-valeryl-LSD (1V-LSD) and 1-cyclopropylmethanoyl-LSD (1cP-LSD)-prediction of toxicological parameters relevant to clinical and forensic toxicology using multi-in silico approach.
- 2.Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).
- 3.Evaluation of 1cp-LSD for Enhancing Welfare in Shelter Dogs: A Randomized Blind Trial with Ethological Intervention.
- 4.Preliminary Findings on Low-Dose 1cp-LSD for Canine Anxiety: Exploring the Role of Owner Neuroticism and Psychopathology.
- 5.A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies.
- 6.Forensic Aspects of Designer LSD Analogs Identification by GC-MS (EI) and UV Spectroscopy.
- 7.Comparative stability assessment of novel LSD analogs in dry blood spots and blood using UHPLC-MS/MS: implications for forensic applications.
- 8.Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
- 9.Crystal Structure of an LSD-Bound Human Serotonin Receptor.
- 10.Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.
10 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is 1cP-LSD basically LSD?
It is thought to convert to LSD in the body and is generally reported as very close in potency and character, though it is a distinct research chemical.
How long does it last?
Like LSD, the full experience commonly runs many hours from a slow onset to a gradual comedown.
Is it safe to redose?
Redosing lysergamides gives diminishing returns due to fast tolerance and can worsen anxiety and sleeplessness; be cautious. This is not medical advice.
Limitations of the evidence
- No formal safety data
Adverse effects
- Anxiety in the wrong setting
- Vasoconstriction
- Insomnia after use